February 5, 2016 7:20am

“Don't bend; don't water it down; don't try to make it logical; don't edit your own soul according to the fashion. Rather, follow your most intense obsessions mercilessly.” ― Franz Kafka

 

Crowd out the noise!  Subscribe … http://www.regmedinvestors.com/create-account ...  Can you afford not to?

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors before the sector and markets open.   

 

 

DOW futures and NASDAQ futures are UP +0.1%

 

U.S. stock index futures indicated a higher open on Friday as traders looked to the release of nonfarm payrolls at 8:30 a.m. ET.

European markets were hovering around the flatline as caution reigns ahead of U.S. jobs data later today. The pan-European STOXX 600 was up around 0.1% after seesawing through the morning.

Asian markets came under pressure on Friday, closing mixed despite a positive finish on Wall Street overnight, as a newly weaker dollar brought fresh concerns.

Data docket; the nonfarm payrolls report, due at 8:30 a.m. Eastern Time. The monthly data set is seen as one of the most important economic updates, as indicates the strength of the labor market and helps the Fed determine whether the economy is strong enough to cope with an interest rate increase.  Expect 180,000 jobs to be added last month, down from 292,000 in December.

 

 

The stem, cell and gene therapy RegMed sector closed POSITIVE on Thursday, NEGATIVE on Wednesday and Tuesday, barely POSITIVE on Monday following a POSITIVE close on last Friday.

 

Past five (5) days (of 43 covered companies):

·         Thursday closed POSITIVE with 9 decliners, 32 advancers and 2 flats;

·         Wednesday closed NEGATIVE with 22 decliners, 20 advancers and 1 flat;

·         Tuesday closed NEGATIVE with 34 decliners, 7 advancers and 2 flats;

·         Monday closed POSITIVE with 19 decliners, 23 advancers and 1 flat;

·         Last, Friday closed POSITIVE with 8 decliners, 32 advancers and 3 flats

 

 

The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector jockeys ride the upside with the downside to photo finishes!

  • A combination of fundamental and technical analysis identifies some candidates however; volatility has distorted historically reliable indicators.

Reiterating - unfortunately, stocks that are leading the sector bounce will be sold on strength and become ripe for being oversold - again!

  • Determine the risk profile that will offer investors the path of the least downside and let me HELP - identify the companies that will least trouble your portfolio <and sleep> in the near future.

 

 

You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you - what are today’s trades?  Friday’s indications:

It’s anybody’s guess …

·         Understanding that speculators are chasing the trade but, strong upsides could be placed on the chopping block …

·         The problem is that a lot of the negatives about falling commodity prices are still being worked into the system;

·         Reiterating, notice how Thursday’s close highlighted the low frequency of moves in the ETFs and indexes - IBB, IWM, IBB and XBI … while the VIX was up a hair;

·         Investors will be dissecting today’s  January jobs report

 

 

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.